8RP.F CELON PHARMA S.A. ZY-10
- Market cap
- EUR 190M
- P/E
- 7.4x
- P/B
- 1.68x
- ROE
- 53.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8RP.F undervalued?
Graham number8RP.F trades 25.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CELON PHARMA S.A. ZY-10 fundamental analysis
No fundamental analysis for CELON PHARMA S.A. ZY-10 yet.
CELON PHARMA S.A. ZY-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CELON PHARMA S.A. ZY-10
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.
Full company profileCELON PHARMA S.A. ZY-10 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CELON PHARMA S.A. ZY-10 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 170M | 162M | 164M | 178M | - | 212M |
| Gross Profit | 108M | 95.5M | 97.6M | 114M | - | 149M |
| Operating Income | -13.6M | -38.0M | -31.0M | -36.8M | -24.9M | -41.1M |
| EBITDA | - | 9.32M | 32.7M | -36.8M | -24.9M | 353M |
| Net Income | -11.6M | -39.3M | -28.1M | -34.4M | -79.4M | 264M |
| EPS | -0.25 | -0.77 | -0.55 | -0.64 | -1.47 | 4.90 |
| Balance Sheet | ||||||
| Total Assets | 682M | 643M | 569M | 544M | 457M | 733M |
| Total Liabilities | 128M | 163M | 124M | 98.6M | 94.2M | 235M |
| Shareholders' Equity | 554M | 480M | 446M | 445M | 363M | 499M |
| Cash & Short-term Investments | 148M | 82.9M | 32.4M | 8.28M | - | 33.5M |
| Cash Flow | ||||||
| Operating Cash Flow | 44.0M | -4.70M | -8.31M | -11.3M | 23.9M | -8.93M |
| Capital Expenditure | 41.4M | 33.9M | 32.8M | 22.8M | 0.00 | 111M |
| Free Cash Flow | 2.60M | -38.6M | -41.1M | -11.3M | 23.9M | -120M |
| Ratios | ||||||
| ROE | -2.1% | -8.2% | -6.3% | -7.7% | -21.8% | 53.0% |
| ROA | -1.7% | -6.1% | -4.9% | -6.3% | -17.3% | 36.0% |
| Net Profit Margin | -6.8% | -24.3% | -17.1% | -19.4% | - | 124.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CELON PHARMA S.A. ZY-10 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 27, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | PLN 4.09M | 0.08 | - |
| 2023 | PLN 4.60M | 0.09 | - |
| 2022 | PLN 14.8M | 0.29 | - |
| 2021 | PLN 3.15M | 0.07 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CELON PHARMA S.A. ZY-10
- Insiders 55.70%
- Institutions 18.27%
- Public & others 26.04%
- Shares outstanding 53.9M
- Free float 23.8M
CELON PHARMA S.A. ZY-10 company profile
- Company name
- CELON PHARMA S.A. ZY-10
- Ticker
- 8RP.F
- ISIN
- PLCLNPH00015
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 560
- Fiscal year end
- December
- Address
- Ogrodowa 2A, Lomianki, Poland, 05-092
- Phone
- 48 227 51 59 33
- Website
- celonpharma.com
About CELON PHARMA S.A. ZY-10
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.
CELON PHARMA S.A. ZY-10 management
1- Dr. Maciej Wieczorek Ph.D.CEO & President of Management Board